| Innate and adaptive immune cells in the tumor microenvironment TF Gajewski, H Schreiber, YX Fu Nature immunology 14 (10), 1014-1022, 2013 | 3876 | 2013 |
| Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy A Sivan, L Corrales, N Hubert, JB Williams, K Aquino-Michaels, ZM Earley, ... Science 350 (6264), 1084-1089, 2015 | 3533 | 2015 |
| Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity S Spranger, R Bao, TF Gajewski Nature 523 (7559), 231-235, 2015 | 2558 | 2015 |
| The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients V Matson, J Fessler, R Bao, T Chongsuwat, Y Zha, ML Alegre, JJ Luke, ... Science 359 (6371), 104-108, 2018 | 2514 | 2018 |
| Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells S Spranger, RM Spaapen, Y Zha, J Williams, Y Meng, TT Ha, TF Gajewski Science translational medicine 5 (200), 200ra116-200ra116, 2013 | 1815 | 2013 |
| STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors L Deng, H Liang, M Xu, X Yang, B Burnette, A Arina, XD Li, H Mauceri, ... Immunity 41 (5), 843-852, 2014 | 1778 | 2014 |
| Tumor and microenvironment evolution during immunotherapy with nivolumab N Riaz, JJ Havel, V Makarov, A Desrichard, WJ Urba, JS Sims, FS Hodi, ... Cell 171 (4), 934-949. e16, 2017 | 1759 | 2017 |
| STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors SR Woo, MB Fuertes, L Corrales, S Spranger, MJ Furdyna, MYK Leung, ... Immunity 41 (5), 830-842, 2014 | 1624 | 2014 |
| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1396 | 2016 |
| Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity L Corrales, LH Glickman, SM McWhirter, DB Kanne, KE Sivick, ... Cell reports 11 (7), 1018-1030, 2015 | 1308 | 2015 |
| Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy A Ribas, R Dummer, I Puzanov, A VanderWalde, RHI Andtbacka, ... Cell 170 (6), 1109-1119. e10, 2017 | 1279 | 2017 |
| Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells MB Fuertes, AK Kacha, J Kline, SR Woo, DM Kranz, KM Murphy, ... Journal of Experimental Medicine 208 (10), 2005-2016, 2011 | 1258 | 2011 |
| Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy S Spranger, D Dai, B Horton, TF Gajewski Cancer cell 31 (5), 711-723. e4, 2017 | 1214 | 2017 |
| Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. TF Gajewski, FW Fitch Journal of immunology (Baltimore, Md.: 1950) 140 (12), 4245-4252, 1988 | 1207 | 1988 |
| Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment H Harlin, Y Meng, AC Peterson, Y Zha, M Tretiakova, C Slingluff, ... Cancer research 69 (7), 3077-3085, 2009 | 1156 | 2009 |
| Helper T cell differentiation is controlled by the cell cycle JJ Bird, DR Brown, AC Mullen, NH Moskowitz, MA Mahowald, JR Sider, ... Immunity 9 (2), 229-237, 1998 | 1056 | 1998 |
| PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells C Blank, I Brown, AC Peterson, M Spiotto, Y Iwai, T Honjo, TF Gajewski Cancer research 64 (3), 1140-1145, 2004 | 1028 | 2004 |
| Cancer classification using the Immunoscore: a worldwide task force J Galon, F Pagès, FM Marincola, HK Angell, M Thurin, A Lugli, I Zlobec, ... Journal of translational medicine 10, 1-10, 2012 | 958 | 2012 |
| Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy C Blank, TF Gajewski, A Mackensen Cancer Immunology, Immunotherapy 54, 307-314, 2005 | 820 | 2005 |
| Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double … GV Long, R Dummer, O Hamid, TF Gajewski, C Caglevic, S Dalle, ... The Lancet Oncology 20 (8), 1083-1097, 2019 | 700 | 2019 |
